



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

May 16, 2019

Geoffrey Kempler  
Chief Executive Officer  
Alterity Therapeutics Ltd.  
ABN 37 080 699 065  
Level 3, 460 Bourke Street, Melbourne  
Victoria 3000 Australia

**Re: Alterity Therapeutics Ltd.  
Registration Statement on Form F-3  
Filed May 13, 2019  
File No. 333-231417**

Dear Mr. Kempler:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Dorrie Yale at 202-551-8776 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Healthcare & Insurance

cc: Steven J. Glusband - Carter Ledyard & Milburn LLP